Aurobindo Pharma arm terminates Ustekinumab biosimilar pact with BioFactura

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-12-27 12:36 GMT | Update On 2025-12-27 12:36 GMT

Hyderabad: Aurobindo Pharma has announced that CuraTeQ Biologics Private Limited, a wholly owned subsidiary of the Company, has mutually agreed to terminate its agreement with BioFactura Inc, USA relating to BFI-751, the proposed ustekinumab biosimilar product.

The company said the decision follows CuraTeQ’s strategic portfolio prioritisation and will not have any material impact on Aurobindo’s overall biosimilars strategy.

The agreement was executed on July 7, 2023, for commercialising BFI-751.

As per the license agreement, BioFactura would receive license fees spread across different milestones leading to commercialization in regulated markets and CuraTeQ to have global manufacturing rights.

Read also: Aurobindo Pharma arm to acquire 20% additional ownership in Luoxin Aurovitas for Rs 45 crore

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 31 manufacturing and packaging facilities that are approved by regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company’s product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a R&D set-up.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Aurobindo Pharma arm terminates Ustekinumab biosimilar pact with BioFactura

Similar News

JnJ discontinues mid stage study of skin disease drug

Codeine cough syrup case: UP court issues notice to attach Rs 30 crore assets of accused

Indian Pharmacopoeia now recognised in 19 countries: JP Nadda

Liv.72 Too Close to Liv.52: Calcutta HC Bars Shimla Drugs from Selling Product Imitating Himalaya

CDSCO Expert Panel Accepts Phase IV Safety Data for Eisai Pharma's Lenvatinib Capsules

UP Drug Dept Probes Rs 72 Cr Fake Medicine Racket, Team Sent to Puducherry to Trace Supply Chain

Eli Lilly, Novo Nordisk race to lock in India obesity drug market